Prot #VAC52416BAC3001: Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease

Project: Research project

Project Details

StatusActive
Effective start/end date1/26/24 → 1/26/27

Funding

  • Pharmaceutical Research Associates, Inc. (Prot #VAC52416BAC3001 // Prot #VAC52416BAC3001)
  • Janssen Research & Development, LLC (Prot #VAC52416BAC3001 // Prot #VAC52416BAC3001)